THE SIGNIFICANCE OF EARLY DIAGNOSTIC BIOMARKERS IN ISCHEMIC HEART DISEASE
Keywords:
Ischemic heart disease, cardiac biomarkers, high-sensitivity cardiac troponin, myocardial injury, acute coronary syndrome, early diagnosis, cardiovascular disease, risk stratification.Abstract
Ischemic heart disease (IHD) is one of the major cardiovascular disorders and remains an important cause of morbidity and mortality worldwide. Early recognition of myocardial ischemia and myocardial injury is essential for initiating timely treatment and reducing the risk of irreversible cardiac damage. However, the clinical presentation of IHD may be variable, and conventional diagnostic methods may have limitations during the earliest stages of myocardial injury. Therefore, circulating biomarkers have become an important component of the early diagnostic assessment of patients with suspected ischemic heart disease. Among currently available biomarkers, high-sensitivity cardiac troponin I and cardiac troponin T are considered the principal biomarkers for detecting myocardial injury because of their high analytical sensitivity and ability to identify small changes in circulating troponin concentrations. Other biomarkers, including creatine kinase-MB, myoglobin, copeptin, natriuretic peptides, inflammatory mediators, and markers of oxidative stress, may provide complementary diagnostic and prognostic information. The integration of biomarker measurements with clinical assessment, electrocardiography, and cardiac imaging can improve diagnostic accuracy and support early risk stratification. Serial measurements of high-sensitivity cardiac troponin are particularly important because dynamic changes in its concentration may help distinguish acute myocardial injury from chronic elevation. Nevertheless, biomarker interpretation can be challenging because increased cardiac troponin concentrations may occur in various cardiovascular and systemic conditions without acute myocardial infarction. This review summarizes the biological basis, diagnostic significance, advantages, and limitations of established and emerging biomarkers in ischemic heart disease, with particular emphasis on their role in early detection and clinical decision-making. A better understanding of these biomarkers may contribute to more accurate and timely recognition of myocardial injury and improve strategies for the early assessment of patients with suspected ischemic heart disease.References
1. Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, White HD, et al. Fourth Universal Definition of Myocardial Infarction (2018). Circulation. 2018
138(20):e618-e651. doi:10.1161/CIR.0000000000000617.
2. Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. European Heart Journal. 2023
44(38):3720-3826. doi:10.1093/eurheartj/ehad191.
3. Gulati M, Levy PD, Mukherjee D, Amsterdam E, Bhatt DL, Birtcher KK, et al. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain. Circulation. 2021
144(22):e368-e454. doi:10.1161/CIR.0000000000001029.
4. Kontos MC, de Lemos JA, Deitelzweig SB, Diercks DB, Gore MO, Hess EP, et al. 2022 ACC Expert Consensus Decision Pathway on the Evaluation and Disposition of Acute Chest Pain in the Emergency Department. Journal of the American College of Cardiology. 2022
80(20):1925-1960. doi:10.1016/j.jacc.2022.08.750.
5. Kaier TE, Twerenbold R, Puelacher C, Marjot J, Imambaccus N, Boeddinghaus J, et al. Direct comparison of cardiac myosin-binding protein C with cardiac troponins for the early diagnosis of acute myocardial infarction. Circulation. 2017
136(16):1495-1508. doi:10.1161/CIRCULATIONAHA.117.028084.
6. Kaier TE, Twerenbold R, Campodarve I, et al. Cardiac myosin-binding protein C in the early diagnosis of acute myocardial infarction. Journal of the American Heart Association. 2019
8(15):e013152. doi:10.1161/JAHA.119.013152.
7. Boeddinghaus J, Nestelberger T, Twerenbold R, et al. A 0/1h-algorithm using cardiac myosin-binding protein C for early diagnosis of myocardial infarction. European Heart Journal Acute Cardiovascular Care. 2022
11(4):325-335. doi:10.1093/ehjacc/zuac014.
8. Akyuz M, et al. Copeptin in acute myocardial infarction: Is there a role in the era of high-sensitivity troponins? [PubMed-indexed review]. 2025.
9. Thygesen K, Alpert JS, Jaffe AS, et al. Fourth Universal Definition of Myocardial Infarction: myocardial injury, acute myocardial injury, and myocardial infarction. European Heart Journal. 2019
40(3):237-269. doi:10.1093/eurheartj/ehy462.
10. Twerenbold R, Boeddinghaus J, Nestelberger T, et al. Clinical use of high-sensitivity cardiac troponin in the evaluation of patients with suspected acute coronary syndrome. [Contemporary diagnostic literature].